Washington, D.C. 20549


FORM 12b-25





[x] Form 10-K [_] Form 20-F [_] Form 11-K [_] Form 10-Q [_] Form N-SAR


For the Period Ended: March 31, 2014


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A




Full Name of Registrant: Aethlon Medical, Inc.


Former Name if Applicable: Not Applicable


Address of Principal Executive Office: 8910 University Center Lane, Suite 660


City, State, and Zip Code: San Diego, CA 92122



PART II – RULES 12b-25(B) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12(b)-25(b), the following should be completed. (Check box if appropriate)


(a) The reasons described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;


[x](b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of the transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and


(c) the accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.






State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof could not be filed within the prescribed time period.


Due to the delays in completing a conversion of a significant note payable and the restructuring of warrants, including waiver of price antidilution protection, held by that note holder, we were delayed in the completion of our fiscal year end audit.




(1) Name and telephone number of person to contact in regard to this notification:


James B. Frakes

Chief Financial Officer

(858) 459-7800


(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed. If the answer is no, identify the report(s):

[x] Yes [_] No


(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[X] Yes [_] No


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


Our change in fair value of derivative liability is expected to increase significantly from the level shown in the fiscal year ended March 31, 2013.


Aethlon Medical, Inc.

(Name of Registrant as specified in charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date: June 30, 2014

/s/ James B. Frakes                                       

By: James B. Frakes

Chief Executive Officer